Relative Efficacy and Safety of Preservative-free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension

Abstract

To assess the relative efficacy and tolerability of preservative-free latanoprost (T2345) compared with other prostaglandin analogues (PGA) for the treatment of open-angle glaucoma and ocular hypertension by adjusted indirect comparison meta-analysis. Randomized, controlled trials evaluating PGA for the treatment of open-angle glaucoma and ocular hypertension were identified by a systematic literature review in MEDLINE, EMBASE, and Cochrane Controlled Trials Register (up to December 2011) databases. The effect size for each treatment and heterogeneity were assessed by classical pairwise meta-analysis (direct comparisons). Adjusted indirect comparisons were performed by using Bucher method. The main endpoints were intraocular pressure (IOP) measured at 3 months and incidence of hyperemia. Twenty-one studies were included in the meta-analysis. No statistically significant differences in IOP at 3 months were seen between T2345 and travoprost [preserved with benzalkonium chloride (BAK), polyquaternium-1 or sofzia], and other BAK-preserved PGA: bimatoprost 0.03%, bimatoprost 0.01%, or latanoprost. T2345 was statistically significantly superior to BAK-tafluprost (mean difference: 0.47 mm Hg, 95% confidence interval, [-1.52;-0.28]). The risk of hyperemia was statistically significantly lower with T2345 than with all the other PGA. Indirect comparisons never found preservative-free latanoprost (T2345) to be statistically significantly inferior to the other PGA in terms of efficacy on IOP and showed statistically significant superiority over BAK-tafluprost. The risk of hyperemia was statistically significantly lower with T2345 than with all the other PGA.